Amlodipine

Generic Name: Amlodipine

Brand Names: Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₂₅ClN_₂O_₅

CAS Number: 88150-42-9

Unique Ingredient Identifier: 1J444QC288

Background: Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers .

Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure . The option for single daily dosing of amlodipine is an attractive feature of this drug .

Indication: Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions :

• Hypertension

• Coronary artery disease

• Chronic stable angina

• Vasospastic angina (Prinzmetal’s or Variant angina)

• Angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%

Associated Conditions: Cardiovascular Events, Chronic Stable Angina Pectoris, Coronary Artery Disease (CAD), Homozygous Familial Hypercholesterolaemia (HoFH), Hypertension, Hypertension, Essential Hypertension, Mixed Dyslipidemias, Primary Hypercholesterolemia, Vasospastic Angina

Clinical Trials

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: Olmesartan
Drug: Amlodipine
Drug: Indapamide
Drug: Zilebesiran
Drug: Placebo

First Posted Date: 2021-11-02

Last Posted Date: 2024-10-16

Lead Sponsor: Alnylam Pharmaceuticals

Target Recruit Count: 672

Registration Number: NCT05103332

Locations: 🇬🇧
Clinical Trial Site, Torpoint, United Kingdom
🇺🇸
Clinical Trials Site, Beverly Hills, California, United States
🇺🇸
Clinical Trial site, Winston-Salem, North Carolina, United States

Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes-----renal Substudy

Phase 4

Withdrawn

Conditions: Diabetes Mellitus, Type 2
Blood Pressure

Interventions: Drug: Allisartan Isoproxil
Drug: Amlodipine

First Posted Date: 2021-07-27

Last Posted Date: 2022-08-26

Lead Sponsor: Guangdong Provincial People's Hospital

Registration Number: NCT04978649

China Stroke Primary Prevention Trial 2 for Participants with Hypertension and MTHFR 677 TT Genotype

Phase 4

Recruiting

Conditions: Hypertension
MTHFR 677 TT Genotype
Hypertension
MTHFR 677 TT Genotype

Interventions: Drug: Amlodipine besylate
Drug: Amlodipine besylate And Folic Acid
Drug: Amlodipine folic acid placebo
Drug: Amlodipine placebo
Drug: 5-methyltetrahydrofolate (5-MTHF)
Drug: 5-MTHF Placebos

First Posted Date: 2021-07-23

Last Posted Date: 2025-02-26

Lead Sponsor: Shenzhen Ausa Pharmed Co.,Ltd

Target Recruit Count: 24000

Registration Number: NCT04974151

Locations: 🇨🇳
First Affillated Hospital of Bengbu Medical University, Bengbu, Anhui, China
🇨🇳
Bozhou People's Hospital, Bozhou, Anhui, China
🇨🇳
Chizhou People's Hospital, Chizhou, Anhui, China

and more 17 locations

China Stroke Primary Prevention Trial 2 for Participants with H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)

Phase 4

Recruiting

Conditions: Hypertension
MTHFR 677 CC or CT Genotype
Elevated Plasma Homocysteine (Hcy≥10µmol/L)
Insufficient Plasma Folate Levels (<12ng/mL)

Interventions: Drug: Amlodipine besylate
Drug: Amlodipine besylate and folic acid
Drug: Amlodipine-folic acid placebos
Drug: Amlodipine placebos

First Posted Date: 2021-07-23

Last Posted Date: 2025-02-26

Lead Sponsor: Shenzhen Ausa Pharmed Co.,Ltd

Target Recruit Count: 32000

Registration Number: NCT04974138

Locations: 🇨🇳
Deyang People's Hospital, Deyang, Sichuan, China
🇨🇳
First Affiliated Hospital of Bengbu Medical University, Bengbu, Anhui, China
🇨🇳
Bozhou, Bozhou, Anhui, China

and more 17 locations